Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21222803 | 1.00 | ROCK2 (0.47) | ROCK2NAMPT | |
| SCHEMBL21222835 | 0.84 | IGF1R (0.36) | — | |
| SCHEMBL21222793 | 0.84 | IGF1R (0.36) | — | |
| SCHEMBL21225889 | 0.82 | NAMPT (0.42) | ROCK2NAMPT | |
| SCHEMBL21223958 | 0.81 | NAMPT (0.41) | ROCK2NAMPT | |
| SCHEMBL28565565 | 0.80 | NAMPT (0.42) | ROCK2NAMPT | |
| SCHEMBL21234153 | 0.79 | PDE3B (0.34) | — | |
| SCHEMBL21233809 | 0.79 | ACVR1 (0.31) | — | |
| SCHEMBL21225886 | 0.77 | ACVR1 (0.34) | — | |
| SCHEMBL21234034 | 0.77 | ACVR1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3746079-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS | Bayer Aktiengesellschaft (DE) | 2020-12-09 | — | — | EP | claimed |
| US-20200360531-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-19 | — | — | US | claimed |
| WO-2019149637-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2019-08-08 | — | — | WO | claimed |
| EP-3746079-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS | Bayer Aktiengesellschaft (DE) | 2020-12-09 | — | — | EP | disclosed |
| CN-112040951-A | Antibody Drug Conjugates (ADC) with NAMPT inhibitors | 拜耳股份公司 | 2020-12-04 | — | — | CN | disclosed |
| US-20200360531-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-19 | — | — | US | disclosed |
| US-20200360531-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-19 | — | — | US | disclosed |
| WO-2019149637-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019149637-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360531-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS | NAMPT, B3GNT2, NQO1 | ROCK2 1686/4885NAMPT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.